Vanguard Capital Management’s Immunovant IMVT Stock Holding History
Bought
Maintained
Sold
Other funds holding IMVT
Vanguard Capital Management's IMVT Position: Q3 2026 in Review
Vanguard Capital Management increased its Immunovant (IMVT) stake by 12% in Q3 2026, buying an estimated $17.7M and bringing the position to 4,087,236 shares worth $138M. The position accounts for ﹤0.01% of the portfolio, ranked #1330.
Vanguard Capital Management first reported a position in IMVT in Q1 2026 and has held it in 3 quarters since. The position peaked at $140M in Q2 2026. 231 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.
- Vanguard Capital Management held 4,087,236 shares of Immunovant worth $138M as of Q3 2026.
- Vanguard Capital Management bought 448,555 Immunovant shares in Q3 2026, an estimated $17.7M.
- Immunovant made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1330 holding.
- Vanguard Capital Management first reported a position in Immunovant in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Immunovant position peaked at $140M in Q2 2026.
- 231 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.